PHARM.ASPHARM.ASAMS
Loading
Net Income Growth Under PressureDecelerating
Percentile Rank72
5Y CAGR+25.5%
Year-over-Year Change
Year-over-year net income growth rate
5Y CAGR
+25.5%/yr
Long-term compound
Percentile
P72
Within normal range
vs 5Y Ago
3.1x
Strong expansion
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | 60.80% |
| Q2 2025 | 131.89% |
| Q1 2025 | -614.83% |
| Q4 2024 | 376.50% |
| Q3 2024 | 13.75% |
| Q2 2024 | 90.35% |
| Q1 2024 | -356.21% |
| Q4 2023 | -178.58% |
| Q3 2023 | 162.62% |
| Q2 2023 | 110.80% |
| Q1 2023 | 16.56% |
| Q4 2022 | -260.75% |
| Q3 2022 | -42.19% |
| Q2 2022 | 354.84% |
| Q1 2022 | 85.98% |
| Q4 2021 | 0.00% |
| Q2 2021 | -30.84% |
| Q1 2021 | -19.45% |
| Q4 2020 | 9.68% |
| Q3 2020 | -13.18% |
| Q2 2020 | 19.54% |
| Q1 2020 | -34.66% |
| Q4 2019 | 30.94% |
| Q3 2019 | 37.71% |
| Q2 2019 | 4.24% |
| Q1 2019 | -49.47% |
| Q4 2018 | 138.99% |
| Q3 2018 | 93.06% |
| Q2 2018 | -20.87% |
| Q1 2018 | 107.94% |
| Q4 2017 | -431.97% |
| Q3 2017 | 65.84% |
| Q2 2017 | -362.77% |
| Q1 2017 | 8.75% |
| Q4 2016 | -59.48% |
| Q3 2016 | -15.51% |
| Q2 2016 | 4.75% |
| Q1 2016 | 9.70% |
| Q4 2015 | -55.82% |
| Q3 2015 | -10.26% |